Bevacizumab Combined with Continuation of EGFR -TKIs in NSCLC Beyond Gradual Progression.
Ziyi XuFei TengXuezhi HaoJunling LiPuyuan XingPublished in: Cancer management and research (2022)
exon19 deletion mutation may benefit more from the combination therapy.